In combination with the numerous anecdotal examples of successful experimental validation of CMAP hypotheses, this increases confidence in the use of CMAP for drug repurposing.
Differences in the proportion of cells that stained positive for each marker may be attributed to the quality of the antibody, in combination with the timing of the sample; for example, cC3 may appear earlier and be more rapidly degraded than cPARP.
For example, everolimus in combination with the non-steroidal aromatase inhibitor letrozole has shown promising clinical efficacy in patients with recurrent endometrial cancer (Slomovitz et al 2011).
Furthermore, the historical isolation of the coastal and offshore zones, in combination with the unique environments of each system (for example; the turbid, low energy water of the Dampier Archipelago, the colder, high energy waters of Ningaloo, or the clear, warm water of the offshore reefs), implies that each zone harbours a unique component of the genetic diversity of this coral reef species.
The examples presented here, in combination with the published applications to real-world metagenomic problems, highlighted the ability of PRICE to maximize the amount of information that can be gathered about a biological sequence and its (meta genomic context given identification of a short sequence of potential interest from a large, complex library of sequences.
For example directional selection, in combination with the effects of limited population size [ 36], might alternatively contribute to this result.
For example, lipophilic drugs in combination with the normal age-related changes to the patient's body composition (eg, the increased proportion of fat mass with loss of lean mass and decreased total body water) tend to result in an increased volume of distribution and a prolonged half-life, whereas water-soluble drugs tend to have a decreased volume of distribution.
More recent trials in our institution concentrate on using Toll-like receptor 7 agonists (Imiquimod) applied to the skin to enhance the migration of DCs, and enhancement of the T-cell responses by infusion of cytokines, for example, IL-2 in combination with the DC vaccines.
For example, induction of RNAi in combination with the virus oncolytic effect may be able to improve response rates seen in human clinical trials with oncolytic viruses.
As an example of how ChemChains, in combination with the Patterns extension, can be used for the above mentioned mutation studies is illustrated on the signal transduction model (mentioned above) in Table 6.
